# iXgene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ixgene

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.ixgene.inc
- Total disclosed funding: $4.5M
- Latest round: Series A (Jan 5, 2023)
- Investors on record: 1

## About

Based in Tokyo, Japan, and founded in 2020 iXgene Inc. provides treatment for intractable brain diseases. In January 2023, iXgene Inc. raised a specific amount in venture funding from investor Keio Innovation Initiative. Other specific investors also participated in the round. As of 2023, the company is headed by its CEO Toshiharu Furukawa who founded the company along with Atsushi Mizuno.

The company develops therapeutic drugs for brain disease treatment such as the recurrence treatment of brain tumors and functional recovery from brain injury. The firm does the treatment using suicidal gene-introduced iPS cell-derived neural stem cells technology.

The company plans to use the January 2023 funding to proceed with non-clinical trials of their genome-edited iPS-derived neural stem cells.

## Funding rounds

- Series A, Jan 5, 2023, $4.5M — Keio Innovation Initiative

## Investors

- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series A